| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/12/2011 | EP2272833A1 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyridin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate |
| 01/12/2011 | EP2272832A1 Phenylpropionic acid derivative and use thereof |
| 01/12/2011 | EP2272829A2 Process for the preparation of pleuromutilins |
| 01/12/2011 | EP2272827A1 Sulphonylpyrroles as hdac inhibitors |
| 01/12/2011 | EP2272826A1 2-mercaptopentancarboxylic acid derivatives, the method for preparing them and the pharmaceutical compositions containing them |
| 01/12/2011 | EP2272825A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation |
| 01/12/2011 | EP2272822A1 Inhibitor of plasminogen activator inhibitor-1 |
| 01/12/2011 | EP2272817A1 Pai-1 inhibitor |
| 01/12/2011 | EP2272535A1 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 01/12/2011 | EP2272529A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272528A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272527A2 Combined DNA vaccine and biological modifiers for cancer therapy |
| 01/12/2011 | EP2272523A1 Compounds, compositions, formulations and process for preparation thereof and method of treatment and management of acidity and related disorders |
| 01/12/2011 | EP2272522A2 Therapeutic compositions for use in prophylaxis or treatment of diarrheas |
| 01/12/2011 | EP2272521A1 Ketone accumulation inhibitor |
| 01/12/2011 | EP2272520A1 Pharmaceutical composition and poria extract useful for enhancing absorption of nutrients |
| 01/12/2011 | EP2272519A1 Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications |
| 01/12/2011 | EP2272518A1 Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same |
| 01/12/2011 | EP2272517A1 Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors |
| 01/12/2011 | EP2272516A2 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
| 01/12/2011 | EP2272515A1 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
| 01/12/2011 | EP2272514A1 Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases |
| 01/12/2011 | EP2272513A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272512A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272511A1 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| 01/12/2011 | EP2272510A1 Inhibitors of the proline racemase of trypanosoma cruzi |
| 01/12/2011 | EP2272509A1 New Uses of metabotropic glutamate receptors |
| 01/12/2011 | EP2272508A2 Pharmaceutical Formulations for Dry Powder Inhalers |
| 01/12/2011 | EP2272507A1 Transdermal formulation comprising an opioid analgesic and an aloe composition |
| 01/12/2011 | EP2272506A2 Microcapsules with modified release of low-solubility active ingredients for oral administration |
| 01/12/2011 | EP2272505A1 Pharmaceutical compositions containing vardenafil hydrochloride trihydrate |
| 01/12/2011 | EP2272504A2 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| 01/12/2011 | EP2272503A2 Oral formulations of cladribine |
| 01/12/2011 | EP2272501A1 Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| 01/12/2011 | EP2272382A1 Composition for promotion of bone growth and maintenance of bone health, comprising soybean or soybean extracts |
| 01/12/2011 | EP2272380A1 Carotenoid compositions dispersed in a matrix comprising starch |
| 01/12/2011 | EP2271677A1 Shear thinning peroxide dispersions |
| 01/12/2011 | EP2271659A1 Compounds for treating pain |
| 01/12/2011 | EP2271658A1 Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| 01/12/2011 | EP2271656A1 2'-o,3'-n-bridged macrolides |
| 01/12/2011 | EP2271650A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| 01/12/2011 | EP2271649A1 Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof |
| 01/12/2011 | EP2271648A1 Isoxazoline linked pyrrolo [2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparattion thereof |
| 01/12/2011 | EP2271647A1 C2-fluoro substituted piperazine linked pyrrolo[2,1-c][1,4] benzodiazepine dimers and a process for the preparation thereof |
| 01/12/2011 | EP2271646A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 01/12/2011 | EP2271645A1 Compounds and compositions as kinase inhibitors |
| 01/12/2011 | EP2271644A1 Substituted piperidines as therapeutic compounds |
| 01/12/2011 | EP2271643A1 Compounds |
| 01/12/2011 | EP2271642A2 Pyridyl inhibitors of hedgehog signalling |
| 01/12/2011 | EP2271640A2 Piperidine derivatives as cgrp receptor antagonists |
| 01/12/2011 | EP2271638A1 Modulators of dopamine neurotransmission |
| 01/12/2011 | EP2271635A1 Modulators of dopamine neurotransmission |
| 01/12/2011 | EP2271634A1 Modulators of dopamine neurotransmission |
| 01/12/2011 | EP2271632A1 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as hdl-cholesterol raising agents |
| 01/12/2011 | EP2271631A2 Inhibitors of protein kinases |
| 01/12/2011 | EP2271630A1 Compounds and compositions as protein kinase inhibitors |
| 01/12/2011 | EP2271629A1 Substituted pyrimidin-5-carboxamides 281 |
| 01/12/2011 | EP2271628A1 Benzimidazole derivatives as calcium channel blockers |
| 01/12/2011 | EP2271627A1 Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties |
| 01/12/2011 | EP2271626A1 Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
| 01/12/2011 | EP2271625A2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| 01/12/2011 | EP2271624A1 Iminopyridine derivatives and use thereof |
| 01/12/2011 | EP2271622A2 Heteroaryl derivatives as cftr modulators |
| 01/12/2011 | EP2271621A1 Pyridyl derivatives as cftr modulators |
| 01/12/2011 | EP2271620A1 Compositions and methods for inhibition of hepatocyte growth factory receptor c-met signaling |
| 01/12/2011 | EP2271619A1 Compounds and compositions as modulators of gpr119 activity |
| 01/12/2011 | EP2271618A1 Pharmaceutical compounds |
| 01/12/2011 | EP2271617A1 Substituted 4-hydroxy-n- (4-hydroxyphenyl) indoles as estrogenic agents |
| 01/12/2011 | EP2271613A1 Hydroxymethylcyclohexyl amines |
| 01/12/2011 | EP2271612A2 Rasagiline mesylate particles and process for the preparation thereof |
| 01/12/2011 | EP2271405A2 Nip thiazole derivatives as inhibitors of 11-beta-hydorxysteroid dehydrogenase-1 |
| 01/12/2011 | EP2271370A2 Compositions and methods for diagnosing and treating melanoma |
| 01/12/2011 | EP2271352A1 Compositions and methods for treatment of neoplastic disease |
| 01/12/2011 | EP2271351A2 Compositions and methods for treating viral infections |
| 01/12/2011 | EP2271350A1 Compositions and methods for immunotherapy |
| 01/12/2011 | EP2271349A1 Compositions and methods for skin care |
| 01/12/2011 | EP2271348A1 Oral and injectable formulations of tetracycline compounds |
| 01/12/2011 | EP2271347A2 Administration of benzodiazepine compositions |
| 01/12/2011 | EP2271346A2 Monocyclic cgrp receptor antagonists |
| 01/12/2011 | EP2271345A1 Hcv ns3 protease inhibitors |
| 01/12/2011 | EP2271344A1 Methods of treating disease-induced ataxia and non-ataxic imbalance |
| 01/12/2011 | EP2271343A1 Salts of 2-substituted quinolines |
| 01/12/2011 | EP2271342A1 Use of nicotinamide for treating summer itch in horses |
| 01/12/2011 | EP2271341A1 Specific inhibitors for vascular endothelial growth factor receptors |
| 01/12/2011 | EP2271340A2 Pharmaceutical preparation comprising stephaglabrin sulfate for treating demyelinating diseases of the nervous system and for promoting restoration of the myelin sheath of nerve fibers |
| 01/12/2011 | EP2271339A1 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors |
| 01/12/2011 | EP2271338A1 Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| 01/12/2011 | EP2271337A1 Beta-turn peptidomimetic cyclic compounds for treating dry eye |
| 01/12/2011 | EP2271336A2 Process for extracting coumarins |
| 01/12/2011 | EP2271335A1 Improved statin production |
| 01/12/2011 | EP2271334A2 Methods of treating fibrotic disorders |
| 01/12/2011 | EP2271333A2 Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells |
| 01/12/2011 | EP2271332A1 Use of compounds in the treatment of tau-induced cytotoxicities |
| 01/12/2011 | EP2271331A1 Compositions and devices for antisepsis and anticoagulation |
| 01/12/2011 | EP2271330A1 Extended release hydrocodone acetaminophen and related methods and uses thereof |
| 01/12/2011 | EP2271329A2 Methods, compositions, and kits for treating pain and pruritis |
| 01/12/2011 | EP2271328A1 Antiseptic compositions for the treatment of infections |
| 01/12/2011 | EP2271327A1 Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction |
| 01/12/2011 | EP2271326A1 Modulation of fibroblast activity |
| 01/12/2011 | EP2271325A1 Methods and use of inducing apoptosis in cancer cells |